124 related articles for article (PubMed ID: 15347897)
1. Aggressive management of recurrent ovarian cancer--the challenge of individualizing cancer therapy illustrated by a case report.
Kieback DG; Einzmann T; Labinsky E; Fischer DC; Niebergall H; Hasenburg A
Onkologie; 2004 Aug; 27(4):393-7. PubMed ID: 15347897
[TBL] [Abstract][Full Text] [Related]
2. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
3. Palliative radiation therapy of symptomatic recurrent bladder cancer.
Yi SK; Yoder M; Zaner K; Hirsch AE
Pain Physician; 2007 Mar; 10(2):285-90. PubMed ID: 17387350
[TBL] [Abstract][Full Text] [Related]
4. Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report.
Camci C; Sevinc A; Aslan Y; Kalender ME; Buyukberber S
Cancer Chemother Pharmacol; 2009 Mar; 63(4):745-8. PubMed ID: 18504578
[TBL] [Abstract][Full Text] [Related]
5. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
6. Attitudes to chemotherapy in patients with ovarian cancer.
Penson RT; Dignan F; Seiden MV; Lee H; Gallagher CJ; Matulonis UA; Olson K; Gibbens I; Gore ME
Gynecol Oncol; 2004 Aug; 94(2):427-35. PubMed ID: 15297184
[TBL] [Abstract][Full Text] [Related]
7. Therapy for recurrent ovarian cancer.
Kuhn WC
Curr Womens Health Rep; 2003 Feb; 3(1):33-8. PubMed ID: 12521548
[TBL] [Abstract][Full Text] [Related]
8. Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience.
Dear RF; Gao B; Harnett P
Asia Pac J Clin Oncol; 2010 Mar; 6(1):66-73. PubMed ID: 20398040
[TBL] [Abstract][Full Text] [Related]
9. Treatment options in patients with recurrent ovarian cancer.
Gadducci A; Conte P; Cianci C; Negri S; Genazzani AR
Anticancer Res; 2001; 21(5):3557-64. PubMed ID: 11848523
[TBL] [Abstract][Full Text] [Related]
10. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.
Harter P; Hilpert F; Mahner S; Heitz F; Pfisterer J; du Bois A
Expert Rev Anticancer Ther; 2010 Jan; 10(1):81-8. PubMed ID: 20014888
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in ovarian cancer patients receiving chemotherapy.
Lakusta CM; Atkinson MJ; Robinson JW; Nation J; Taenzer PA; Campo MG
Gynecol Oncol; 2001 Jun; 81(3):490-5. PubMed ID: 11371144
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
14. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.
Hensley ML; Hoppe B; Leon L; Sabbatini P; Aghajanian C; Chi D; Spriggs DR
Gynecol Oncol; 2001 Sep; 82(3):464-9. PubMed ID: 11520141
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
[TBL] [Abstract][Full Text] [Related]
18. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
19. Current concepts of treatment strategies in advanced or recurrent ovarian cancer.
Salzberg M; Thurlimann B; Bonnefois H; Fink D; Rochlitz C; von Moos R; Senn H
Oncology; 2005; 68(4-6):293-8. PubMed ID: 16020955
[TBL] [Abstract][Full Text] [Related]
20. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
Markman M; Markman J; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
J Clin Oncol; 2004 Aug; 22(15):3120-5. PubMed ID: 15284263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]